Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.5400+0.0800 (+2.31%)
At close: 04:00PM EDT
3.5000 -0.04 (-1.13%)
After hours: 07:34PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close3.4600
Open3.4600
Bid3.4900 x 1000
Ask3.5400 x 1800
Day's Range3.3000 - 3.5650
52 Week Range2.5400 - 112.8700
Volume622,765
Avg. Volume896,175
Market Cap194.148M
Beta (5Y Monthly)0.84
PE Ratio (TTM)N/A
EPS (TTM)-7.5880
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.11
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ALLK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Allakos Inc.
    Daily – Vickers Top Buyers & Sellers for 03/09/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results

    SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2022. Recent Allakos Events Submitted End-of-Phase 2 briefing package to FDA to discuss Phase 2 KRYPTOS data and development pathway of lirentelimab in patients with eosinophil

  • GlobeNewswire

    Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors

    SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the appointment of Amy L. Ladd, M.D., orthopaedic surgeon and professor at Stanford University, to the Allakos board of directors. “We are very pleased to have such an accomplished physician as Dr. Ladd join our board. Her extensive medical background and expert

  • Simply Wall St.

    Companies Like Allakos (NASDAQ:ALLK) Could Be Quite Risky

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Advertisement
Advertisement